Promising phase 1/2 results for entrectinib against ROS1+ non-small cell lung cancer

Entrectinib in ROS1-positive non-small cell lung cancer (NSCLC) shows response rate of 77.4 percent, with median duration of response of 24.6 months

CRISPR screen reveals new targets in more than half of all squamous cell carcinomas

The path to a therapy against ΔNp63α seems clear: activate TGFB2 and RHOA.

New combination treatment targets pre-leukemia stem cells

“We hope that omacetaxine and venetoclax will be a potent combination against advanced MDS,” says Craig Jordan, PhD.

Thomas Flaig, MD, helps to define standards of cancer care in Africa

Thomas Flaig, MD, recently returned from a trip to Ghana with the African Cancer Coalition, where he met with a panel of six African physicians to localize NCCN genitourinary (GU) cancer treatment guidelines for use in Sub-Saharan Africa.

Latest News from the University of Colorado Cancer Center

@CUCancerCenter on Twitter